VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen

Cancer Chemother Pharmacol. 1989;24(5):338-9. doi: 10.1007/BF00304770.

Abstract

A total of 20 patients with intermediate or high-grade non-Hodgkin's lymphomas who failed to LNH 84 regimen were treated with a combination of VP 16, ifosfamide and methotrexate (VIM regimen). Nineteen patients are evaluable for response. Eight patients (42%) achieved complete responses and four (21%) attained partial responses. Most of the complete responders are still in remission with a follow-up of more than 30 months for 5 patients.

Publication types

  • Comparative Study

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Follow-Up Studies
  • Humans
  • Ifosfamide / administration & dosage
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Methotrexate / administration & dosage
  • Prednisolone / administration & dosage
  • Remission Induction
  • Vindesine / administration & dosage

Substances

  • Bleomycin
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • Vindesine
  • Ifosfamide
  • Methotrexate

Supplementary concepts

  • LNH 84 protocol